T

Trevi Therapeutics
D

TRVI

12.880
USD
-0.03
(-0.23%)
مفتوح الان
حجم التداول
19,770
الربح لكل سهم
-1
العائد الربحي
-
P/E
-35
حجم السوق
1,650,321,825
المقالات

العنوان: Trevi Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.